Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Aflibercept (Eylea®) injection	TA305 - Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion TA346 - Aflibercept for treating diabetic macular oedema TA294 - Aflibercept solution for injection for treating wet age-related macular degeneration TA409 - Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion TA486 - Aflibercept for treating choroidal neovascularisation
Alemtuzumab concentrate for infusion	TA312 - Alemtuzumab for treating relapsing-remitting multiple sclerosis	Hospital use only
Alirocumab (Praluent®)	TA393 - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia	To be used in line with NICE TA
Alitretinoin 30mg capsules	TA177 - Alitretinoin for the treatment of severe chronic hand eczema
Alpelisib	TA816: Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer
Alteplase injection	TA52 - Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction	Hospital use only
Anakinra (Kineret®)	TA685 - Anakinra for treating Still’s disease
Anastrozole tablets	TA112 - Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Andexanet alfa (Ondexxya®)	TA697 - Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban
Apalutamide	TA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.